The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: A systematic review

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.

Original languageEnglish
Pages (from-to)1552-1557
Number of pages6
JournalCurrent Drug Targets
Volume14
Issue number13
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Metabolism
Rheumatoid Arthritis
Bone
Tumor Necrosis Factor-alpha
Bone and Bones
Bone Remodeling
Therapeutics
Bone Resorption
Interleukin-1
Bone Density
Osteoporosis
Minerals
Databases
Cytokines
Research

Keywords

  • Bone mineral density
  • Osteoporosis
  • Rheumatoid arthritis
  • TNF α antagonists

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

@article{352ff382be9948dba4dc2ed1f90aa312,
title = "The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: A systematic review",
abstract = "Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.",
keywords = "Bone mineral density, Osteoporosis, Rheumatoid arthritis, TNF α antagonists",
author = "Sakthiswary Rajalingham and Srijit Das",
year = "2013",
month = "12",
doi = "10.2174/13894501113149990176",
language = "English",
volume = "14",
pages = "1552--1557",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis

T2 - A systematic review

AU - Rajalingham, Sakthiswary

AU - Das, Srijit

PY - 2013/12

Y1 - 2013/12

N2 - Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.

AB - Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.

KW - Bone mineral density

KW - Osteoporosis

KW - Rheumatoid arthritis

KW - TNF α antagonists

UR - http://www.scopus.com/inward/record.url?scp=84889047524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889047524&partnerID=8YFLogxK

U2 - 10.2174/13894501113149990176

DO - 10.2174/13894501113149990176

M3 - Article

C2 - 23848441

AN - SCOPUS:84889047524

VL - 14

SP - 1552

EP - 1557

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -